4
Changes in Ownership
IRulya Therapeutics Inc. Filed Acc 0001209191-21-007540
Chief Executive Officer sold 60,000 shares at an average $38.49 ($2,309,600)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Lynch Casey Chief Executive Officer | 2021-02-01 | Sale | −4,686 | $34.60 | $162,136 | 1,094,088 | I: show line 1 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-01 | Sale | −3,100 | $35.59 | $110,329 | 1,090,988 | I: show line 2 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-01 | Sale | −7,460 | $36.56 | $272,738 | 1,083,528 | I: show line 3 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-01 | Sale | −4,283 | $37.68 | $161,383 | 1,079,245 | I: show line 4 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-01 | Sale | −100 | $38.28 | $3,828 | 1,079,145 | I: show line 5 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-01 | Sale | −371 | $39.23 | $14,554 | 1,078,774 | I: show line 6 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-02 | Sale | −14,929 | $36.02 | $537,743 | 1,063,845 | I: show line 7 in the form |
| Lynch Casey Chief Executive Officer | 2021-02-02 | Sale | −5,071 | $36.75 | $186,359 | 1,058,774 | I: show line 8 in the form |
| Open-market sales · 60,000 sh · avg $38.49 · $2,309,600 | |||||||
Loading xslF345X03/doc4.xml…